Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To investigate the long-term effects of induction therapy with adalimumab (ADA) plus
methotrexate (MTX) in comparison with placebo (PBO) plus MTX in DMARD-naïve patients
with active early rheumatoid arthritis (RA).